Holen Sie sich die Stockscreener-App
0.9856
4.31%
-0.0444
Handel nachbörslich:
.98
-0.0056
-0.57%
Schlusskurs vom Vortag:
$1.03
Offen:
$1.05
24-Stunden-Volumen:
1.07M
Relative Volume:
1.70
Marktkapitalisierung:
$104.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.91M
KGV:
-4.48
EPS:
-0.22
Netto-Cashflow:
$-19.57M
1W Leistung:
+21.71%
1M Leistung:
+58.13%
6M Leistung:
-23.00%
1J Leistung:
-38.78%
1-Tages-Spanne:
$0.96
$1.06
1-Wochen-Bereich:
$0.8057
$1.07
52-Wochen-Spanne:
$0.5526
$1.71
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
10202 5TH AVENUE NE, SEATTLE, WA
Vergleichen Sie ATOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.9856 | 104.60M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
561.75 | 34.75B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.40 | 33.69B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Atossa Therapeutics (ATOS) Reports Promising Phase 2 Trial Resul - GuruFocus
Atossa Therapeutics Announces Full Results from I?SPY?2 Endocrin - GuruFocus
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - PR Newswire
Wells Fargo & Company MN Has $68,000 Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Atossa Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus
ATOSSA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - Morningstar
Barclays PLC Has $181,000 Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Monday - Defense World
Atossa Therapeutics reports progress in breast cancer treatments - MSN
Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Mid Florida Newspapers
JPMorgan Chase & Co. Buys 211,654 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen F - GuruFocus
ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen Formulations | ATOS Stock News - GuruFocus
A look into Atossa Therapeutics Inc (ATOS)’s deeper side - Sete News
LPL Financial LLC Cuts Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics Inc (ATOS)’s results reveal risk - uspostnews.com
Atossa Therapeutics Inc (ATOS) rating initates by Maxim Group - knoxdaily.com
Sector Update: Health Care - marketscreener.com
Atossa Therapeutics (ATOS) Secures Patent for Key Breast Cancer Drug Formulations - GuruFocus
Atossa stock gains on U.S. patent win (ATOS:NASDAQ) - Seeking Alpha
Atossa Therapeutics Inc (ATOS) Stock: Navigating a Year of Volatility - investchronicle.com
Atossa Therapeutics Gets US Patent Covering (Z)-endoxifen Breast Cancer Treatment - marketscreener.com
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281 - GuruFocus
Atossa Therapeutics (ATOS) Secures Patent for Innovative Drug Fo - GuruFocus
Atossa Therapeutics secures new patent for breast cancer drug By Investing.com - Investing.com India
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio | ATOS Stock News - GuruFocus
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio - The Manila Times
Atossa Therapeutics secures new patent for breast cancer drug - Investing.com Australia
Major Patent Breakthrough: Atossa's Cancer Drug Portfolio Expands with 58 New Protected Formulations - Stock Titan
Atossa Therapeutics Proposes Potentially Groundbreaking Study Ai - GuruFocus
Atossa Therapeutics (ATOS) Launches SMART 2.0 Phase 3 Clinical S - GuruFocus
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 - The Manila Times
Revolutionary Breast Cancer Prevention Trial Could Reduce Risk by 20% in High-Risk Women - Stock Titan
Hilton (NYSE:HLT) Reports Sales Below Analyst Estimates In Q1 Earnings - The Globe and Mail
Renaissance Technologies LLC Boosts Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Stock Performance Spotlight: Atossa Therapeutics Inc (ATOS) Ends the Day at 0.73, Down by -0.73 - DWinneX
ATOS’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
Atossa Therapeutics announces issuance of U.S. patent - MSN
Research Analysts Issue Forecasts for ATOS Q1 Earnings - The AM Reporter
Ascendiant Capital Markets Comments on ATOS Q1 Earnings - Defense World
Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $7.25 at Ascendiant Capital Markets - American Banking and Market News
What was Atossa Therapeutics Inc (ATOS)’s performance in the last session? - uspostnews.com
Plus Therapeutics Strengthens Board: Former Atossa CFO Brings 30 Years of NYSE and NASDAQ Leadership - Stock Titan
Atossa Therapeutics secures new patent for breast cancer treatment By Investing.com - Investing.com South Africa
Atossa Therapeutics (ATOS) Secures New U.S. Patent for (Z)-endoxifen Formulations - GuruFocus
Atossa Therapeutics secures new patent for breast cancer treatment - Investing.com
Atossa Therapeutics (ATOS) Secures Patent for New (Z)-endoxifen Formulation | ATOS Stock News - GuruFocus
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio - The Manila Times
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275 - GuruFocus
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):